VPM1002

Vaccine Platform

Mycobacterial – Live Attenuated

Phase of Development

Phase 3

Candidate Overview

VPM1002 is a recombinant, urease C-deficient, listeriolysin expressing BCG vaccine strain and was generated in order to induce a broader immune response against mycobacterial antigens.

Sponsor / Lead Developer: Serum Institute of India Private Limited

Development partner(s): Vakzine Projekt Management GmbH

Primary Indication: Prevention of Mtb infection or sustained infection

Other Indication(s): Prevention of TB disease and Prevention of TB recurrence

Target Population(s): Adolescents, Adults, Children, Elderly, Infants, and People cured of active TB

Clinical Trials

ACTIVE TRIALS
Registry NumberCTRI/2019/01/017026
Clinical Trial PhasePhase 3
StatusActive
Primary endpoint(s) for this clinical trialPrevention of TB disease
Target population(s) for clinical trialAdults
Adolescents
_________________________
Registry NumberNCT04351685
Clinical Trial Phase3
StatusActive
Primary endpoint(s) for this clinical trialPrevention of Mtb infection or sustained infection
Target population(s) for clinical trialInfants
_________________________
Registry NumberNCT03152903 / CTRI/2017/03/008266/
Clinical Trial PhasePhase 2/3
StatusActive
Primary endpoint(s) for this clinical trialPrevention of TB recurrence
Target population(s) for clinical trialAdults
People cured of active TB
COMPLETED TRIALS
Registry NumberNCT02391415
Clinical Trial PhasePhase 2b
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialInfants
_________________________
Registry NumberNCT01479972
Clinical Trial PhasePhase 2a
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialInfants
_________________________
Registry NumberNCT01113281
Clinical Trial PhasePhase 1
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults
_________________________
Registry NumberNCT00749034
Clinical Trial PhasePhase 1
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults

Additional Information

A Phase 3 trial of VPM1002 has been completed to assess the reduction of days with severe respiratory infectious diseases at hospital and/or at home in elderly participants during the SARS-CoV-2 pandemic (EudraCT 2020-001675-33)